97 results
8-K
EX-10.1
CNSP
Cns Pharmaceuticals Inc
3 May 24
Departure of Directors or Certain Officers
4:26pm
to such person.
2.10“Director” means a director of the Company who is not an employee of the Company or a Subsidiary.
2.11“Exchange Act” means the Securities … or any successor provision.
2.14“Key Employee” means an employee of the Company or any Subsidiary selected to participate in the Plan in accordance
8-K
EX-99.1
CNSP
Cns Pharmaceuticals Inc
1 Apr 24
Berubicin study enrollment completed; Topline data expected in first half of 2025
5:01pm
, $488,000 in employee compensation, $141,000 in stock-based compensation and $92,000 in insurance expenses. These changes were offset by increases
8-K
EX-1.1
dwccjnsx
2 Feb 24
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-10.1
u9l7c3937i4
2 Feb 24
Entry into a Material Definitive Agreement
5:00pm
424B4
x7522clpk
31 Jan 24
Prospectus supplement with pricing info
4:27pm
8-K
4f5lohl
23 Jan 24
Departure of Directors or Certain Officers
4:01pm
S-8
a4ao3i1wn5n
21 Nov 23
Registration of securities for employees
9:11pm
8-K
EX-4.1
d2d32a94
17 Oct 23
Entry into a Material Definitive Agreement
8:00am